Qube Research & Technologies Ltd Purchases 25,550 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Qube Research & Technologies Ltd raised its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 544.1% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 30,246 shares of the biopharmaceutical company’s stock after acquiring an additional 25,550 shares during the period. Qube Research & Technologies Ltd’s holdings in Ultragenyx Pharmaceutical were worth $2,884,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its stake in shares of Ultragenyx Pharmaceutical by 12.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,671,786 shares of the biopharmaceutical company’s stock valued at $1,215,090,000 after purchasing an additional 1,201,294 shares during the period. Ergoteles LLC raised its stake in shares of Ultragenyx Pharmaceutical by 1,523.6% during the 2nd quarter. Ergoteles LLC now owns 155,864 shares of the biopharmaceutical company’s stock valued at $14,862,000 after purchasing an additional 146,264 shares during the period. SG Americas Securities LLC raised its stake in shares of Ultragenyx Pharmaceutical by 929.4% during the 2nd quarter. SG Americas Securities LLC now owns 137,084 shares of the biopharmaceutical company’s stock valued at $13,071,000 after purchasing an additional 123,767 shares during the period. Sectoral Asset Management Inc bought a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at $12,775,000. Finally, Geode Capital Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 10.2% during the 1st quarter. Geode Capital Management LLC now owns 1,076,533 shares of the biopharmaceutical company’s stock valued at $122,574,000 after purchasing an additional 99,514 shares during the period. Hedge funds and other institutional investors own 95.57% of the company’s stock.

A number of research firms recently issued reports on RARE. Bank of America upgraded Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and set a $162.00 price objective on the stock in a research note on Tuesday, June 29th. TheStreet cut Ultragenyx Pharmaceutical from a “c-” rating to a “d” rating in a research report on Tuesday, August 17th. HC Wainwright started coverage on Ultragenyx Pharmaceutical in a research report on Thursday, September 30th. They set a “buy” rating and a $106.00 target price for the company. Zacks Investment Research cut Ultragenyx Pharmaceutical from a “hold” rating to a “strong sell” rating and set a $92.00 target price for the company. in a research report on Wednesday, July 14th. Finally, SVB Leerink restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, October 5th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $132.78.

RARE opened at $81.08 on Thursday. The stock has a 50-day moving average price of $91.72 and a 200-day moving average price of $96.87. Ultragenyx Pharmaceutical Inc. has a 12-month low of $76.78 and a 12-month high of $179.65. The stock has a market capitalization of $5.50 billion, a P/E ratio of -15.18 and a beta of 1.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Sunday, August 1st. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.53). The company had revenue of $86.98 million for the quarter, compared to analysts’ expectations of $85.88 million. Ultragenyx Pharmaceutical had a negative net margin of 97.79% and a negative return on equity of 40.48%. The company’s revenue was up 40.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.41 earnings per share. Research analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.76 EPS for the current fiscal year.

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 7,336 shares of the company’s stock in a transaction that occurred on Wednesday, September 8th. The stock was sold at an average price of $100.65, for a total transaction of $738,368.40. Following the completion of the transaction, the executive vice president now owns 36,004 shares of the company’s stock, valued at approximately $3,623,802.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Camille L. Bedrosian sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, September 1st. The shares were sold at an average price of $100.03, for a total value of $250,075.00. The disclosure for this sale can be found here. Corporate insiders own 6.70% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII.

See Also: VIX – Volatility Index

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.